#MITIGATE subgroup analysis: Inebilizumab reduced flares & boosted remission across all #IgG4-RD subgroups. HR for flare vs PBO: 0.12-0.16 across sex/race. Similar results for all subgroups in achieving flare-free, treatment-free complete remission. @RheumNow #EULAR2025 #OP0189

There is still hope for vagal nerve stimulation in RA! RCT RESET-RA 240+pts multibioIR Implantable cervical device Meets Primary endpoint ACR 20 wk12 Subgroup 1 prior bioDMARD ACR 20 wk12 46% vs 19% sham EULAR Good response 61% vs 42% sham Wk 12 SAE rate 1.7% #OP0190 #EULAR2025 https://t.co/DCON01XXgd

• https://x.com/AurelieRheumo/status/1933085839317143937/photo/1
• https://x.com/AurelieRheumo/status/1933085839317143937/photo/1
• https://x.com/AurelieRheumo/status/1933085839317143937/photo/1
• https://x.com/AurelieRheumo/status/1933085839317143937/photo/1

2-year #MANDARA data: Benralizumab shows durable remission, eosinophil suppression & OGC-sparing in EGPA. ~62-68% in remission at wk104. Low relapse rate, no loss of asthma control or decline of lung function. No new safety signals. @RheumNow #EULAR2025 #OP0166 https://t.co/kXh2q2ilJF

• https://x.com/DrMiniDey/status/1933080330883453155/photo/1

In SLEek LTE, ABBV-599 HD (BTKi+JAKi) & UPA 30mg sustained or improved disease control through 104wks: SRI-4 ≥82%, ↓flares, near steroid-free, no new safety signals. PBO-switchers improved too. Targeted oral combos look promising. @RheumNow #EULAR2025 #OP0198 https://t.co/IHXC2iD0h6

• https://x.com/DrMiniDey/status/1933081588700439034/photo/1

#EULAR2025 Abstr#OP0006. There is no standardised definition for complete renal response in #lupus nephritis. Post-hoc analysis of REGENCY showed Obinutuzumab + SOC was superior to PBO + SOC if endpoints for voclosporin and belimumab RCTs were used. Effect size ~13-16% @RheumNow https://t.co/q8MNAV8XF3

• https://x.com/Yuz6Yusof/status/1932929355761520692/photo/1

T2T in #gout w serum #uric #acid / #urate target SAVES LIVES Study of achievement of target 🎯 ⬇️CVE and death If not achieving Urate <360 T2T also reduced baseline #SUA #EULAR2025 @rheumnow abst#OP0005 https://t.co/ePchJ4vqnU

• https://x.com/Janetbirdope/status/1932879622661693936/photo/1

Secukinumab for PMR? -post hoc analysis of the TitAIN study (phase 2 RCT on new onset/relapsing GCA) showed: -Numerical reduction in patients experiencing PMR symptoms when treated with secukinumab compared to placebo. -Safety profile was similar to the overall GCA study

SPEED RCT: In early PsA with poor prognostic factors, PASDAS at 24wks: •Early TNFi: 3.7 •Combo csDMARDs: 4.1 •Step-up csDMARDs: 4.7 Early TNFi beat step-up by -1.09 (p<0.001); combo csDMARDs also superior (-0.69, p=0.02). Early TNFi benefit sustained at 48wks. Abstract#OP0089 https://t.co/MpazF8BIr2

• https://x.com/synovialjoints/status/1932915635928940957/photo/1

In vitro, balinatunfib (TNFR1-selective inhibitor) preserved Treg expansion in CD4+ T cells co-cultured with IL-2 and memTNF (Treg 8.99 percent, p<0.0001), unlike adalimumab and etanercept which reduced Tregs by 27.5 to 41 percent. Confirms TNFR2 sparing with selective TNFR1 https://t.co/xaczz87Xrd

• https://x.com/synovialjoints/status/1932918407331979266/photo/1

#EULAR2025 Abstr#OP0002 Promising new mode of action therapy for #myositis. Phase 2 RCT of efgartigimod (FcRn-i; coformulated with recombinant PH20) showed improvement in TIS & other key endpoints vs PBO at Wk24. Injection reaction common (23%). Will proceed to Phase 3 @RheumNow https://t.co/SuMolfcDkS

• https://x.com/Yuz6Yusof/status/1932923552182698074/photo/1

Phase 3 of POETYK-PsA-2: -Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to placebo in multiple PsA domains. -Clinical efficacy maintained until week 52. -No major safety signals reported. -Notably high placebo response rates. Abstract

📊 In a 40-yr cohort (n=2818), RA pts had 2.3x ↑ risk of DVT (HR 2.26) & 1.6x ↑ risk of PE (HR 1.61) vs non-RA. Risk ↑ with RF/CCP+, nodules (HR 2.9), BMI ≥30 (HR 1.9), & biologic use in year 1 (HR 2.4–2.9). Remission = ↓ PE risk (HR 0.47) 📍OP0070 @RheumNow #EULAR2025

POS0627: RA patients aged ≥90 yrs can benefit from biologics/JAKi! In 3,600 pts, 84% of those ≥90 achieved low disease activity, 71% were on JAKi. But serious infections occurred in 21%—mostly pneumonia. Use w/caution in the oldest-old. #EULAR2025 @rheumnow